Lincoln Pharma Q3FY26: PAT Jumps 37.7%, Revenue Up 13%

💊

reported a strong Q3FY26 performance with consolidated net profit rising 37.70% YoY to ₹28.60 crore. Revenue from operations grew 13.49% to ₹166.32 crore, driven by healthy traction across key therapeutic segments and improved operational performance.